A vaccine that comprises a dendritic cell (DC)-specific antibody to which an engineered antigen comprising Cyclin D1 is attached to form an antibody-antigen complex. The Cyclin D1 has been engineered to be less susceptible to proteolytic degradation by eliminating one or more proteolytic sites.